论文部分内容阅读
目的探讨骨髓增生异常综合征的临床特征。方法回顾分析我院2004年1月至2010年2月收治75例MDS患者。结果 75例MDS分型中RA35例占46%,RAEB24例占32%,RAEB-T12例占16%,RAS2例占3%,CMML2例占3%。结论虽然目前除骨髓移植外,尚有化疗、抗血管生成药物、造血刺激因子、诱导分化剂等方法,但由于MDS患者多数年龄较大,病程中会出现感染、出血、铁负荷过多等,因此治疗上可供选用的毒副作用较小的方案不多。尤其对于高龄患者,这类患者往往同时具有多种基础疾病,重要脏器功能处于边缘状态,无法采用常规的一些治疗方案,因此目前支持治疗仍然是主要甚至唯一的方法。影响预后的因素与疾病的自然病程、临床特征、骨髓及外周血中原始细胞的水平、细胞遗传学异常以及细胞减少的系列数等均有关。
Objective To investigate the clinical features of myelodysplastic syndromes. Methods Retrospective analysis of our hospital from January 2004 to February 2010 admitted to 75 cases of MDS patients. Results 75 cases of MDS type RA35 46%, RAEB 24 cases accounted for 32%, RAEB-T12 16%, RAS2 3%, CMML2 3%. Conclusions Although there are chemotherapy, antiangiogenic drugs, hematopoietic stimulating factors and differentiation inducing agents in addition to bone marrow transplantation, most patients with MDS have infection, bleeding and excessive iron load due to their age. Therefore, the treatment of available options for side effects of small programs. Especially for the elderly patients, such patients often have multiple underlying diseases at the same time. The function of vital organs is marginalized and conventional treatment methods can not be used. Therefore, the current supportive treatment is still the main or even the only one. Factors affecting the prognosis of the disease’s natural history, clinical features, bone marrow and peripheral blood in the level of primitive cells, cytogenetic abnormalities, and the number of cells decreased series and so on.